



July 31, 2026

To,
Listing Operation Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001
(Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (East), Mumbai-400051
(SYMBOL: CORONA)

Dear Sir / Madam,

Sub.: Outcome of the Board Meeting

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we would like to inform that based on the recommendation of the Audit Committee, the Board at its meeting held today has, inter alia, approved the unaudited standalone and consolidated financial results along with limited review reports of the Company for the first quarter and three months ended June 30, 2026. The said financial results are enclosed herewith.

In terms of Regulation 47 of the Listing Regulations, the Company will publish an advertisement for unaudited standalone and consolidated financial results for the first quarter and three months ended June 30, 2026.

The above results along with limited review reports are also being made available on the website of the Company at www.coronaremedies.com

A Press Release on financial results which is being submitted to the media, is also enclosed herewith.

The Board meeting commenced at 03:00 p.m. and concluded at 04:00 p.m.

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For CORONA Remedies Limited

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a

Walker Chandiook & Co LLP

Block No. D/15th Floor,
Cabin No. A5 to A7
"West Gate" Near YMCA Club,
S.G Highway, Sarkhej Road,
Ahmedabad-380015
Gujarat, India

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of CORONA Remedies Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited) ('the Company') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). Attention is drawn to the fact that the figures for the corresponding quarter ended 30 June 2025 have been approved by the Company's Board of Directors, but have not been subjected to audit or review.
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Page 1 of 2

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Guwahati, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

CORONA Remedies Limited
Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial
Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (as amended) (Contd.)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The audit of standalone financial results for the year ended 31 March 2026 and review of unaudited financial results for the quarter ended 31 March 2026 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who have expressed unmodified opinion vide their audit report dated 11 May 2026 and unmodified conclusion vide their review report dated 11 May 2026, respectively, whose report has been furnished to us by the management, and which has been relied upon by us for the purpose of our review of the Statement.

Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013



Mehulkumar Sharadkumar Janani
Partner
Membership No. 118617
UDIN: 26118617NYUQIC6771



Place: Ahmedabad
Date: 31 July 2026

**CORONA Remedies Limited**

(formerly known as CORONA Remedies Private Limited)

Regd. Office: CORONA House,

C - Mondeal Business Park, Near Gurudwara, S.G.Highway,

Thaltej, Ahmedabad-380059, Gujarat, India

Tele.: +079-40233000 | Website : www.coronaremedies.com

CIN : L24231GJ2004PLC044656

Statement of Standalone Unaudited Financial Results for the Quarter ended 30 June 2026

(Amount Rs. in Crores except per share data)

Sr. No.	Particulars	For Quarter Ended			For Year Ended
		30 June 2026 (Unaudited)	31 March 2026 (Refer note 4)	30 June 2025 (Refer note 5)	31 March 2026 (Audited)
1	Income :				
	Revenue from operations	422.43	353.09	346.54	1,403.18
	Other income	3.15	4.11	2.02	10.65
	Total income	425.58	357.20	348.56	1,413.83
2	Expenses :				
	Cost of materials consumed	32.65	27.73	25.07	103.51
	Purchases of Stock-in-trade	57.20	46.34	34.77	150.38
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(12.33)	(7.83)	5.94	7.05
	Employee benefits expense	122.09	106.63	97.44	403.02
	Finance costs	2.69	1.38	1.99	6.97
	Depreciation and amortization expenses	13.24	10.29	8.92	37.87
	Other expenses	129.69	118.20	113.54	445.78
	Total expenses	345.23	302.74	287.67	1,154.58
3	Profit before exceptional item and tax (1-2)	80.35	54.46	60.89	259.25
4	Exceptional item :				
	Statutory impact of new Labour Codes (Refer note 6)	-	-	-	(19.10)
5	Profit before tax (3+4)	80.35	54.46	60.89	240.15
6	Tax expense :				
	Current tax	18.38	4.23	14.30	51.48
	Deferred tax	1.87	5.18	0.19	3.82
	Total Tax expense	20.25	9.41	14.49	55.30
7	Net Profit after tax for the period / year (5-6)	60.10	45.05	46.40	184.85
8	Other comprehensive income / (loss) for the period/year				
	Items that will not be reclassified to profit or loss				
	Remeasurement of net defined benefit plans	(0.40)	0.90	(1.08)	0.15
	Income tax effect on above	0.10	(0.23)	0.27	(0.04)
	Total other comprehensive income / (loss) for the period/year, net of tax	(0.30)	0.67	(0.81)	0.11
9	Total comprehensive income for the period/year (7+8)	59.80	45.72	45.59	184.96
10	Paid-up equity share capital (face value Rs.10/-)	61.16	61.16	61.16	61.16
11	Other Equity				684.81
12	Earnings per share (not annualised for the quarter)				
	Basic (Rs.)	9.83	7.37	7.59	30.22
	Diluted (Rs.)	9.83	7.37	7.59	30.22



Notes to Standalone Financial Results for the Quarter ended 30 June 2026 :

- 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders.
- 2 The above standalone unaudited financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 31 July 2026.
- 3 These standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- 4 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended 31 December 2025 which were subjected to limited review.
- 5 The figures for the quarter ended 30 June 2025 as reported in the Statement have been approved by the Company's Board of Directors but have not been subjected to review since the requirement of submission of quarterly standalone financial results is applicable on listing of equity shares of the Company from the quarter ended 30 September 2025.
- 6 On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" amounting Rs.19.10 crores (Post tax Rs.14.29 crores) in the financial results for the year ended 31 March 2026. The incremental impact consisting of gratuity of Rs.13.60 crores and long-term compensated absences of Rs.5.50 crores primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
- 7 The Company has only one reportable business segment namely - 'Pharmaceuticals' as determined by the Chief Operating Decision Maker in accordance with the Ind AS 108-"Operating Segment".

For CORONA Remedies Limited,



Nirav K. Mehta
Managing Director & CEO
DIN : 01644041

Place: Ahmedabad
Date : 31 July 2026



Walker ChandioK & Co LLP

Block No. D/15th Floor,
Cabin No. A5 to A7
"West Gate" Near YMCA Club,
S.G Highway, Sarkhej Road,
Ahmedabad-380015
Gujarat, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of CORONA Remedies Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited) ('the Holding Company') and its associate (refer Annexure 1 for the list of associate included in the Statement) for the quarter ended 30 June 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



CORONA Remedies Limited
Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial
Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (as amended) (Contd.)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement includes the Holding Company's share of net profit after tax of ₹ 0.01 crores and total comprehensive income of ₹ 0.01 Crores for the quarter ended 30 June 2026, in respect of one (1) associate, based on their interim financial information, which have not been reviewed by their auditor, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associate, is based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, this interim financial information is not material to the Holding Company.

Our conclusion is not modified in respect of this matter with respect to our reliance on the financial information certified by the Board of Directors.

6. The Statement includes figures for the quarter ended 30 June 2025, which are based on special purpose interim consolidated financial statements of the Holding Company for the quarter ended 30 June 2025, which were audited by the predecessor auditor, Deloitte Haskins & Sells LLP, who have expressed an unmodified opinion vide their audit report dated 26 August 2025. Their report has been furnished to us and has been relied upon by us for the purpose of our review of the Statement.

Our conclusion is not modified in respect of this matter



CORONA Remedies Limited
Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial
Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (as amended) (Contd.)

7. The audit of consolidated financial results for the year ended 31 March 2026 and review of unaudited financial results for the quarter ended 31 March 2026 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who have expressed unmodified opinion vide their audit report dated 11 May 2026 and unmodified conclusion vide their review report dated 11 May 2026, respectively, whose report has been furnished to us by the management, and which has been relied upon by us for the purpose of our review of the Statement.

Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013



Mehulkumar Sharadkumar Janani
Partner
Membership No. 118617
UDIN : 26118617QXGQDE1472



Place : Ahmedabad
Date : 31 July 2026

CORONA Remedies Limited
Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial
Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (as amended) (Contd.)

Annexure 1

List of the entities included in Statement

Sr. No.	Entity Name	Relationship
1.	CORONA Remedies Limited	Holding Company
2.	La Chandra Pharmalab Private Limited	Associate






CORONA Remedies Limited
(formerly known as CORONA Remedies Private Limited)
Regd. Office: CORONA House,
C - Mondeal Business Park, Near Gurudwara, S.G.Highway,
Thaltej, Ahmedabad-380059, Gujarat, India
Tele.: +079-40233000 | Website : www.coronaremedies.com
CIN : L24231GJ2004PLC044656

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30 June 2026

(Amount Rs. in Crores except per share data)

Sr. No.	Particulars	For Quarter Ended			For Year Ended
		30 June 2026 (Unaudited)	31 March 2026 (Refer note 4)	30 June 2025 (Refer note 5)	31 March 2026 (Audited)
1	Income :				
	Revenue from operations	422.43	353.09	346.54	1,403.18
	Other income	3.15	4.11	2.02	10.65
	Total income	425.58	357.20	348.56	1,413.83
2	Expenses :				
	Cost of materials consumed	32.65	27.73	25.07	103.51
	Purchases of Stock-in-trade	57.20	46.34	34.77	150.38
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(12.33)	(7.83)	5.94	7.05
	Employee benefits expense	122.09	106.63	97.44	403.02
	Finance costs	2.69	1.38	1.99	6.97
	Depreciation and amortization expenses	13.24	10.29	8.92	37.87
	Other expenses	129.69	118.20	113.54	445.78
	Total expenses	345.23	302.74	287.67	1,154.58
3	Profit before Share of profit/(loss) of associate, exceptional item and tax (1-2)	80.35	54.46	60.89	259.25
4	Exceptional item :				
	Statutory impact of new Labour Codes (Refer note 6)	-	-	-	(19.10)
5	Share of profit/(loss) of associate (net of tax)	0.01	0.28	(0.20)	0.27
6	Profit before tax (3+4+5)	80.36	54.74	60.69	240.42
7	Tax expense :				
	Current tax	18.38	4.23	14.30	51.48
	Deferred tax	1.87	5.18	0.19	3.82
	Total Tax expense	20.25	9.41	14.49	55.30
8	Net Profit after tax for the period / year (6-7)	60.11	45.33	46.20	185.12
9	Other comprehensive income / (loss) for the period/year				
	Items that will not be reclassified to profit or loss				
	Remeasurement of net defined benefit plans	(0.40)	0.90	(1.08)	0.15
	Income tax effect on above	0.10	(0.23)	0.27	(0.04)
	Share of other comprehensive income of associate (net of tax)	0.00	0.00	0.00	0.00
	Total other comprehensive income / (loss) for the period/year, net of tax	(0.30)	0.67	(0.81)	0.11
10	Total comprehensive income for the period/year (8+9)	59.81	46.00	45.39	185.23
11	Profit for the year/period attributable to:				
	Owners of the Company	60.11	45.33	46.20	185.12
		60.11	45.33	46.20	185.12
12	Other comprehensive income / (loss) for the period/year attributable to:				
	Owners of the Company	(0.30)	0.67	(0.81)	0.11
		(0.30)	0.67	(0.81)	0.11
13	Total comprehensive income for the period/year attributable to:				
	Owners of the Company	59.81	46.00	45.39	185.23
		59.81	46.00	45.39	185.23
14	Paid-up equity share capital (face value Rs.10/-)	61.16	61.16	61.16	61.16
15	Other Equity				685.70
16	Earnings per share (not annualised for the quarter)				
	Basic (Rs.)	9.83	7.41	7.55	30.27
	Diluted (Rs.)	9.83	7.41	7.55	30.27



Notes to Consolidated Financial Results for the Quarter ended 30 June 2026 :

- 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders.
- 2 The above consolidated unaudited financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 31 July 2026.
- 3 These consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- 4 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended 31 December 2025 which were subjected to limited review.
- 5 The consolidated financial results for the quarter ended 30 June 2025 have been extracted from the audited special purpose interim financial statements which were prepared for IPO filings.
- 6 On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" amounting Rs.19.10 crores (Post tax Rs.14.29 crores) in the financial results for the year ended 31 March 2026. The incremental impact consisting of gratuity of Rs.13.60 crores and long-term compensated absences of Rs.5.50 crores primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
- 7 The Company has only one reportable business segment namely - 'Pharmaceuticals' as determined by the Chief Operating Decision Maker in accordance with the Ind AS 108-"Operating Segment".

For CORONA Remedies Limited,



Nirav K. Mehta
Managing Director & CEO
DIN : 01644041

Place: Ahmedabad
Date : 31 July 2026



PRESS RELEASE

CORONA Remedies delivers a strong start to FY 27, with a **Revenue growth of 21.9% and a PAT growth of 30.1% Y-o-Y** for Q1FY27, driven by robust Brand Building and Operational Excellence

Ahmedabad | July 31, 2026

CORONA Remedies Limited, a leading India-focused branded pharmaceutical company, announced its unaudited financial results for Q1FY27, delivering robust revenue and resilient margins, supported by **consistent brand-building, focus on engine brands and enhanced operational efficiencies**.

Key Operational & Financial Highlights

- Delivered ₹ 422.4 Cr revenue for Q1FY27 registering a **growth of 21.9% Y-o-Y** supported by execution excellence and focused brand building initiatives.
- PAT for Q1FY27 stood at ₹ 60.1Cr, a **growth of 30.1% Y-o-Y**. PAT margins for Q1FY27 stood at 14.2%, an increase of **90 bps Y-o-Y**.

Financial Performance Snapshot:

Particulars (₹ in Cr)	Q1FY27	Q1FY26	Y-o-Y % Growth
Revenue from Operations	422.4	346.5	21.9%
EBITDA	93.1	69.8	33.5%
EBITDA Margin	22.0%	20.1%	190 bps
Profit After Tax	60.1	46.2	30.1%
Profit After Tax Margin	14.2%	13.3%	90 bps

Key Business Highlights:

- Outpacing IPM Growth¹:** CORONA continues to be the **fastest growing** company among top 30 companies of IPM **for last 6 consecutive months**, as per MAT June'26. CORONA has outperformed market **by 1.9 times** as per MAT June'26.
- Market Rank Progression¹:** Rank moves **3 places up** in a year and reaches at **26th Rank** as per MAT June'26 and for the quarter (We were at 29th Rank as of MAT June'25).
- Therapy Leadership¹:** CORONA stands at **5th rank in Gynaecology**; reflecting our commitment and therapy leadership in the segment.
- Inauguration of Female Hormone Plant:** Inaugurated and initiated the commercialization of our EU-GMP approved Female Hormone Manufacturing Facility based in Ahmedabad, on **30 June 2026**.
- Integration of Wokadine** (acquired brand): We have initiated the smooth integration of Wokadine from the supply side and distribution perspective.

¹: As per Pharmatrac June'26 Data

Commenting on the performance for Q1FY27, **Mr. Nirav K. Mehta, Managing Director & CEO**, CORONA Remedies Limited, said:

“Q1 FY27 shows our commitment to consistent growth with operational excellence and brand building. With robust revenue growth and market rank improvement, we see positive outcomes of the strategies in place.

We aim to move steadfast with our aligned focus on core therapies such as Women’s Healthcare, Cardio-diabetes, Pain Management and Urology. We are also strengthening ourselves in Infertility and Biosimilar segment.”

About CORONA Remedies Limited

Founded in 2004, CORONA Remedies Limited is a leading India-focused pharmaceutical company engaged in developing, manufacturing, and marketing products across key therapeutic areas including women’s healthcare, cardio-diabetes, pain management and urology.

The company operates WHO-GMP/EU GMP-certified manufacturing facilities and maintains strong innovation capabilities through DSIR-approved R&D centers.

Disclaimer: Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management’s current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

For further information, please contact

Company	Investor Relations Advisors
CORONA Remedies Limited CIN: L24231GJ2004PLC044656 Chetna Dharajiya – Company Secretary & Compliance Officer	Strategic Growth Advisors Pvt Ltd. CIN: U74140MH2010PTC204285 Sagar Shroff / Tanay Shah Email id: sagar.shroff@sgapl.net / tanay.shah@sgapl.net Tel No: +91 98205 19303 / +91 98333 91899